A classifier combining the expression signature of RPL39L, RPL26L1, and RPL21 has an even greater predictive power, comparable to that of genes that are most predictive [47] for the relapse-free survival of breast cancer patients (Fig. 6g). This evidence concerns the gene RPL26L1 and breast carcinoma.